Annamaria Vezzani

List of Publications by Year
in descending order

258	30,445	3933 88	4991 167
papers	citations	h-index	g-index

267	267	267	19069
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The <scp>ENIGMAâ€Epilepsy</scp> working group: Mapping disease from large data sets. Human Brain Mapping, 2022, 43, 113-128.	3.6	47
2	A systemsâ€level analysis highlights microglial activation as a modifying factor in common epilepsies. Neuropathology and Applied Neurobiology, 2022, 48, .	3.2	22
3	Highâ€mobility group box 1 as a predictive biomarker for drugâ€resistant epilepsy: A proofâ€ofâ€concept study. Epilepsia, 2022, 63, e1.	5.1	17
4	Lipid mediator nâ€3 docosapentaenoic acidâ€derived protectin D1 enhances synaptic inhibition of hippocampal principal neurons by interaction with a Gâ€proteinâ€coupled receptor. FASEB Journal, 2022, 36, e22203.	0.5	6
5	A mathematical model of neuroimmune interactions in epileptogenesis for discovering treatment strategies. IScience, 2022, 25, 104343.	4.1	1
6	A team science approach to discover novel targets for infantile spasms (IS). Epilepsia Open, 2021, 6, 49-61.	2.4	3
7	The association between systemic autoimmune disorders and epilepsy and its clinical implications. Brain, 2021, 144, 372-390.	7.6	23
8	Chromosome 14 deletions, rings, and epilepsy genes: A riddle wrapped in a mystery inside an enigma. Epilepsia, 2021, 62, 25-40.	5.1	4
9	Proposal to optimize evaluation and treatment of Febrile infectionâ€related epilepsy syndrome (FIRES): A Report from FIRES workshop. Epilepsia Open, 2021, 6, 62-72.	2.4	35
10	Emerging Molecular Mechanisms of Neuroinflammation in Seizure Disorders. Agents and Actions Supplements, 2021, , 21-43.	0.2	1
11	Climate change and epilepsy: Insights from clinical and basic science studies. Epilepsy and Behavior, 2021, 116, 107791.	1.7	30
12	In-depth characterization of a mouse model of post-traumatic epilepsy for biomarker and drug discovery. Acta Neuropathologica Communications, 2021, 9, 76.	5.2	20
13	Antiepileptogenesis and disease modification: Progress, challenges, and the path forwardâ€”Report of the Preclinical Working Group of the 2018 NINDSâ€sponsored antiepileptogenesis and disease modification workshop. Epilepsia Open, 2021, 6, 276-296.	2.4	24
14	Microglia proliferation plays distinct roles in acquired epilepsy depending on disease stages. Epilepsia, 2021, 62, 1931-1945.	5.1	33
15	Targeting Oxidative Stress with Antioxidant Duotherapy after Experimental Traumatic Brain Injury. International Journal of Molecular Sciences, 2021, 22, 10555.	4.1	6
16	Safety and Efficacy of Natalizumab as Adjunctive Therapy for People With Drug-Resistant Epilepsy. Neurology, 2021, 97, e1757-e1767.	1.1	15
17	CXCL1-CXCR1/2 signaling is induced in human temporal lobe epilepsy and contributes to seizures in a murine model of acquired epilepsy. Neurobiology of Disease, 2021, 158, 105468.	4.4	15
18	Inflammation and reactive oxygen species as disease modifiers in epilepsy. Neuropharmacology, 2020, 167, 107742.	4.1	121

#	Article	IF	Citations
19	Brain Inflammation and Seizures: Evolving Concepts and New Findings in the Last 2 Decades. Epilepsy Currents, 2020, 20, 40S-43S.	0.8	21
20	White matter abnormalities across different epilepsy syndromes in adults: an ENIGMA-Epilepsy study. Brain, 2020, 143, 2454-2473.	7.6	123
21	Drug Resistance in Epilepsy: Clinical Impact, Potential Mechanisms, and New Innovative Treatment Options. Pharmacological Reviews, 2020, 72, 606-638.	16.0	360
22	Repurposed molecules for antiepileptogenesis: Missing an opportunity to prevent epilepsy?. Epilepsia, 2020, 61, 359-386.	5.1	57
23	TLR3 preconditioning induces anti-inflammatory and anti-ictogenic effects in mice mediated by the IRF3/IFN-Î² axis. Brain, Behavior, and Immunity, 2019, 81, 598-607.	4.1	14
24	Neuroinflammatory pathways as treatment targets and biomarkers in epilepsy. Nature Reviews Neurology, 2019, 15, 459-472.	10.1	463
25	Inflammation and reactive oxygen species in status epilepticus: Biomarkers and implications for therapy. Epilepsy and Behavior, 2019, 101, 106275.	1.7	67
26	Targeting oxidative stress improves disease outcomes in a rat model of acquired epilepsy. Brain, 2019, 142, e39-e39.	7.6	137
27	Therapeutic effect of Anakinra in the relapsing chronic phase of febrile infectionâ€“related epilepsy syndrome. Epilepsia Open, 2019, 4, 344-350.	2.4	85
28	Editorial: Experimental Models of Epilepsy and Related Comorbidities. Frontiers in Pharmacology, 2019, 10, 179.	3.5	3
29	Febrile Response and Seizures. , 2019, , 403-411.		1
30	Characterisation of an infantile rat model of de novo status epilepticus: long-term outcomes. Epilepsy and Behavior, 2019, 101, 106744.	1.7	0
31	Changes of dimension of EEG/ECoG nonlinear dynamics predict epileptogenesis and therapy outcomes. Neurobiology of Disease, 2019, 124, 373-378.	4.4	10
32	Oxidative stress and inflammation in a spectrum of epileptogenic cortical malformations: molecular insights into their interdependence. Brain Pathology, 2019, 29, 351-365.	4.1	54
33	Molecular isoforms of high-mobility group box 1 are mechanistic biomarkers for epilepsy. Journal of Clinical Investigation, 2019, 129, 2166-2166.	8.2	11
34	Development of In Vivo Imaging Tools for Investigating Astrocyte Activation in Epileptogenesis. Molecular Neurobiology, 2018, 55, 4463-4472.	4.0	4
35	Intrinsic Inflammation Is a Potential Anti-Epileptogenic Target in the Organotypic Hippocampal Slice Model. Neurotherapeutics, 2018, 15, 470-488.	4.4	27
36	mi<scp>R</scp>147b: <scp>A</scp> novel key regulator of interleukin 1 betaâ€mediated inflammation in human astrocytes. Glia, 2018, 66, 1082-1097.	4.9	28

#	Article	IF	Citations
37	Neuroinflammation Alters Integrative Properties of Rat Hippocampal Pyramidal Cells. Molecular Neurobiology, 2018, 55, 7500-7511.	4.0	36
38	Structural brain abnormalities in the common epilepsies assessed in a worldwide ENIGMA study. Brain, 2018, 141, 391-408.	7.6	352
39	Commonalities in epileptogenic processes from different acute brain insults: Do they translate?. Epilepsia, 2018, 59, 37-66.	5.1	206
40	Epilepsy. Nature Reviews Disease Primers, 2018, 4, 18024.	30.5	541
41	High Mobility Group Box 1 is a novel pathogenic factor and a mechanistic biomarker for epilepsy. Brain, Behavior, and Immunity, 2018, 72, 14-21.	4.1	97
42	Review: Neuroinflammatory pathways as treatment targets and biomarker candidates in epilepsy: emerging evidence from preclinical and clinical studies. Neuropathology and Applied Neurobiology, 2018, 44, 91-111.	3.2	186
43	Inhibition of monoacylglycerol lipase terminates diazepamâ€resistant status epilepticus in mice and its effects are potentiated by a ketogenic diet. Epilepsia, 2018, 59, 79-91.	5.1	37
44	n-3 Docosapentaenoic acid-derived protectin D1 promotes resolution of neuroinflammation and arrests epileptogenesis. Brain, 2018, 141, 3130-3143.	7.6	55
45	Ictogenic and Epileptogenic Mechanisms of Neuroinflammation. , 2018, , 23-31.		0
46	Pharmacological targeting of brain inflammation in epilepsy: Therapeutic perspectives from experimental and clinical studies. Epilepsia Open, 2018, 3, 133-142.	2.4	68
47	Inflammation and Epilepsy: Preclinical Findings and Potential Clinical Translation. Current Pharmaceutical Design, 2018, 23, 5569-5576.	1.9	74
48	Common data elements and data management: Remedy to cure underpowered preclinical studies. Epilepsy Research, 2017, 129, 87-90.	1.6	35
49	Biomarkers of Epileptogenesis: The Focus on Glia and Cognitive Dysfunctions. Neurochemical Research, 2017, 42, 2089-2098.	3.3	18
50	Electrocorticographic Dynamics as a Novel Biomarker in Five Models of Epileptogenesis. Journal of Neuroscience, 2017, 37, 4450-4461.	3.6	50
51	Febrile Infectionâ€"Related Epilepsy Syndrome: Clinical Review and Hypotheses of Epileptogenesis. Neuropediatrics, 2017, 48, 005-018.	0.6	89
52	Blockade of the IL-1R1/TLR4 pathway mediates disease-modification therapeutic effects in a model of acquired epilepsy. Neurobiology of Disease, 2017, 99, 12-23.	4.4	149
53	Inhibition of IL-1Î² Signaling Normalizes NMDA-Dependent Neurotransmission and Reduces Seizure Susceptibility in a Mouse Model of Creutzfeldtâ€"Jakob Disease. Journal of Neuroscience, 2017, 37, 10278-10289.	3.6	28
54	Introduction to the 2nd Meeting on Immunity and Inflammation in Epilepsy (<scp>IIE</scp>2016). Epilepsia, 2017, 58, 7-10.	5.1	5

#	Article	IF	Citations
55	Neuroinflammatory targets and treatments for epilepsy validated in experimental models. Epilepsia, 2017, 58, 27-38.	5.1	131
56	Molecular isoforms of high-mobility group box 1 are mechanistic biomarkers for epilepsy. Journal of Clinical Investigation, 2017, 127, 2118-2132.	8.2	90
57	Epigenetic control of epileptogenesis by miR-146a. Oncotarget, 2017, 8, 45040-45041.	1.8	13
58	2014 Epilepsy Benchmarks Area II: Prevent Epilepsy and Its Progression. Epilepsy Currents, 2016, 16, 187-191.	0.8	11
59	Preventing epileptogenesis: A realistic goal?. Pharmacological Research, 2016, 110, 96-100.	7.1	47
60	Cognitive deficits and brain myo-Inositol are early biomarkers of epileptogenesis in a rat model of epilepsy. Neurobiology of Disease, 2016, 93, 146-155.	4.4	54
61	Febrile infectionâ€related epilepsy syndrome treated with anakinra. Annals of Neurology, 2016, 80, 939-945.	5.3	208
62	Advances in the development of biomarkers for epilepsy. Lancet Neurology, The, 2016, 15, 843-856.	10.2	283
63	Modulation of neuronal excitability by immune mediators in epilepsy. Current Opinion in Pharmacology, 2016, 26, 118-123.	3.5	98
64	Current understanding and neurobiology of epileptic encephalopathies. Neurobiology of Disease, 2016, 92, 72-89.	4.4	71
65	Immunity and Inflammation in Epilepsy. Cold Spring Harbor Perspectives in Medicine, 2016, 6, a022699.	6.2	162
66	Proteomic profiling of epileptogenesis in a rat model: Focus on inflammation. Brain, Behavior, and Immunity, 2016, 53, 138-158.	4.1	70
67	Infections, inflammation and epilepsy. Acta Neuropathologica, 2016, 131, 211-234.	7.7	348
68	Anti-inflammatory drugs in epilepsy: does it impact epileptogenesis?. Expert Opinion on Drug Safety, 2015, 14, 583-592.	2.4	61
69	GABAA currents are decreased by IL-1Î² in epileptogenic tissue of patients with temporal lobe epilepsy: implications for ictogenesis. Neurobiology of Disease, 2015, 82, 311-320.	4.4	129
70	The immunoproteasome Î²5i subunit is a key contributor to ictogenesis in a rat model of chronic epilepsy. Brain, Behavior, and Immunity, 2015, 49, 188-196.	4.1	30
71	Albumin induces excitatory synaptogenesis through astrocytic TGF-Î²/ALK5 signaling in a model of acquired epilepsy following bloodâ€“brain barrier dysfunction. Neurobiology of Disease, 2015, 78, 115-125.	4.4	213
72	Neurologyâ€”the next 10 years. Nature Reviews Neurology, 2015, 11, 658-664.	10.1	7

#	Article	IF	Citations
73	Immunity and inflammation in status epilepticus and its sequelae: possibilities for therapeutic application. Expert Review of Neurotherapeutics, 2015, 15, 1081-1092.	2.8	84
74	Neuromodulatory properties of inflammatory cytokines and their impact on neuronal excitability. Neuropharmacology, 2015, 96, 70-82.	4.1	473
75	Inflammation and Immunomodulation in Epilepsy and Its Comorbidities. , 2015, , 155-174.		4
76	Epilepsy and Inflammation in the Brain: Overview and Pathophysiology. Epilepsy Currents, 2014, 14, 3-7.	0.8	162
77	Does Brain Inflammation Mediate Pathological Outcomes in Epilepsy?. Advances in Experimental Medicine and Biology, 2014, 813, 169-183.	1.6	49
78	The role of reflex control of immunity in the anticonvulsive effects of vagus nerve stimulation. Journal of Neuroimmunology, 2014, 275, 149-150.	2.3	0
79	Disulfide-Containing High Mobility Group Box-1 PromotesN-Methyl-<scp>d</scp>-Aspartate Receptor Function and Excitotoxicity by Activating Toll-Like Receptor 4-Dependent Signaling in Hippocampal Neurons. Antioxidants and Redox Signaling, 2014, 21, 1726-1740.	5.4	141
80	Novel Concepts in Epileptogenesis and its Prevention. Neurotherapeutics, 2014, 11, 229-230.	4.4	9
81	Epilepsy and brain inflammation. Experimental Neurology, 2013, 244, 11-21.	4.1	466
82	Receptor for Advanced Glycation Endproducts is upregulated in temporal lobe epilepsy and contributes to experimental seizures. Neurobiology of Disease, 2013, 58, 102-114.	4.4	139
83	Pharmacological blockade of IL-1Î²/IL-1 receptor type 1 axis during epileptogenesis provides neuroprotection in two rat models of temporal lobe epilepsy. Neurobiology of Disease, 2013, 59, 183-193.	4.4	154
84	Epilepsy biomarkers. Epilepsia, 2013, 54, 61-69.	5.1	215
85	Fetal brain inflammation may prime hyperexcitability and behavioral dysfunction later in life. Annals of Neurology, 2013, 74, 1-3.	5.3	11
86	The role of inflammation in epileptogenesis. Neuropharmacology, 2013, 69, 16-24.	4.1	393
87	Glia and epilepsy: excitability and inflammation. Trends in Neurosciences, 2013, 36, 174-184.	8.6	656
88	The dual role of TNF-Î± and its receptors in seizures. Experimental Neurology, 2013, 247, 267-271.	4.1	67
89	Immunity Activation in Brain Cells in Epilepsy: Mechanistic Insights and Pathological Consequences. Neuropediatrics, 2013, 44, 330-335.	0.6	13
90	Before Epilepsy Unfolds: Finding the epileptogenesis switch. Nature Medicine, 2012, 18, 1626-1627.	30.7	25

#	Article	IF	Citations
91	Longâ€lasting proâ€ictogenic effects induced in vivo by rat brain exposure to serum albumin in the absence of concomitant pathology. Epilepsia, 2012, 53, 1887-1897.	5.1	94
92	In vivo imaging of glia activation using ¹Hâ€magnetic resonance spectroscopy to detect putative biomarkers of tissue epileptogenicity. Epilepsia, 2012, 53, 1907-1916.	5.1	75
93	Bloodâ€“brain barrier dysfunctionâ€“induced inflammatory signaling in brain pathology and epileptogenesis. Epilepsia, 2012, 53, 37-44.	5.1	111
94	Inflammation and epilepsy. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2012, 107, 163-175.	1.8	69
95	Brain Autonomous Mechanisms of Seizure-Induced BBB Dysfunction. Epilepsy Currents, 2012, 12, 69-71.	0.8	4
96	Astrocyte immune responses in epilepsy. Glia, 2012, 60, 1258-1268.	4.9	168
97	Seizureâ€induced brainâ€borne inflammation sustains seizure recurrence and bloodâ€“brain barrier damage. Annals of Neurology, 2012, 72, 82-90.	5.3	218
98	WONOEP XI: Workshop summary by the Scientific Organizing Committee. Epilepsia, 2012, 53, 1275-1276.	5.1	1
99	Finding a better drug for epilepsy: Antiinflammatory targets. Epilepsia, 2012, 53, 1113-1118.	5.1	44
100	Epileptic Encephalitis: The Role of the Innate and Adaptive Immune System. Brain Pathology, 2012, 22, 412-421.	4.1	25
101	Gliaâ€“Neuron Interactions in Ictogenesis and Epileptogenesis. , 2012, , 618-634.		23
102	IL-1 receptor/Toll-like receptor signaling in infection, inflammation, stress and neurodegeneration couples hyperexcitability and seizures. Brain, Behavior, and Immunity, 2011, 25, 1281-1289.	4.1	334
103	Inflammation and prevention of epileptogenesis. Neuroscience Letters, 2011, 497, 223-230.	2.1	172
104	Brain inflammation as a biomarker in epilepsy. Biomarkers in Medicine, 2011, 5, 607-614.	1.4	182
105	The role of inflammation in epilepsy. Nature Reviews Neurology, 2011, 7, 31-40.	10.1	1,442
106	Interleukin-1 type 1 receptor/Toll-like receptor signalling in epilepsy: the importance of IL-1beta and high-mobility group box 1. Journal of Internal Medicine, 2011, 270, 319-326.	6.0	157
107	The clinicopathologic spectrum of focal cortical dysplasias: A consensus classification proposed by an ad hoc Task Force of the ILAE Diagnostic Methods Commission1. Epilepsia, 2011, 52, 158-174.	5.1	1,454
108	Introduction. Epilepsia, 2011, 52, 1-4.	5.1	43

#	Article	IF	Citations
109	General conclusions. Epilepsia, 2011, 52, 52-53.	5.1	1
110	Therapeutic potential of new antiinflammatory drugs. Epilepsia, 2011, 52, 67-69.	5.1	44
111	IL-1Î² is induced in reactive astrocytes in the somatosensory cortex of rats with genetic absence epilepsy at the onset of spike-and-wave discharges, and contributes to their occurrence. Neurobiology of Disease, 2011, 44, 259-269.	4.4	85
112	Acute encephalopathy with inflammation-mediated status epilepticus. Lancet Neurology, The, 2011, 10, 99-108.	10.2	251
113	High-mobility group box-1 impairs memory in mice through both toll-like receptor 4 and Receptor for Advanced Glycation End Products. Experimental Neurology, 2011, 232, 143-148.	4.1	159
114	Interleukin-1Î² Biosynthesis Inhibition Reduces Acute Seizures and Drug Resistant Chronic Epileptic Activity in Mice. Neurotherapeutics, 2011, 8, 304-315.	4.4	260
115	Misplaced NMDA receptors in epileptogenesis contribute to excitotoxicity. Neurobiology of Disease, 2011, 43, 507-515.	4.4	91
116	Status epilepticus-induced pathologic plasticity in a rat model of focal cortical dysplasia. Brain, 2011, 134, 2828-2843.	7.6	54
117	Activation of toll-like receptor, RAGE and HMGB1 signalling in malformations of cortical development. Brain, 2011, 134, 1015-1032.	7.6	180
118	Glia-neuron interactions in epilepsy: Inflammatory mediators. Epilepsia, 2010, 51, 55-55.	5.1	4
119	Gene therapy of focal-onset epilepsy by adeno-associated virus vector-mediated overexpression of neuropeptide Y. Epilepsia, 2010, 51, 96-96.	5.1	1
120	Neuronal hyperexcitability and seizures are associated with changes in glialâ€“neuronal interactions in the hippocampus of a mouse model of epilepsy with mental retardation. Journal of Neurochemistry, 2010, 115, 1445-1454.	3.9	17
121	Anticonvulsant effects and behavioural outcomes of rAAV serotype 1 vector-mediated neuropeptide Y overexpression in rat hippocampus. Gene Therapy, 2010, 17, 643-652.	4.5	62
122	Toll-like receptor 4 and high-mobility group box-1 are involved in ictogenesis and can be targeted to reduce seizures. Nature Medicine, 2010, 16, 413-419.	30.7	777
123	Epileptogenesis Provoked by Prolonged Experimental Febrile Seizures: Mechanisms and Biomarkers. Journal of Neuroscience, 2010, 30, 7484-7494.	3.6	228
124	Brain Inflammation and Epilepsy. , 2010, , 45-59.		5
125	ICE/caspase 1 inhibitors and IL-1beta receptor antagonists as potential therapeutics in epilepsy. Current Opinion in Investigational Drugs, 2010, 11, 43-50.	2.3	55
126	Basic mechanisms ofÂMCD inÂanimal models. Epileptic Disorders, 2009, 11, 206-214.	1.3	14

#	Article	IF	Citations
127	Age-dependent vascular changes induced by status epilepticus in rat forebrain: Implications for epileptogenesis. Neurobiology of Disease, 2009, 34, 121-132.	4.4	86
128	Leukocyteâ€“Endothelial Adhesion Mechanisms in Epilepsy: Cheers and Jeers. Epilepsy Currents, 2009, 9, 118-121.	0.8	11
129	Pilocarpine-Induced Seizures Revisited: What Does the Model Mimic?. Epilepsy Currents, 2009, 9, 146-148.	0.8	30
130	Basic mechanisms of status epilepticus due to infection and inflammation. Epilepsia, 2009, 50, 56-57.	5.1	47
131	Neuropeptide Y Overexpression Using Recombinant Adenoassociated Viral Vectors. Neurotherapeutics, 2009, 6, 300-306.	4.4	32
132	Molecular and functional interactions between tumor necrosis factor-alpha receptors and the glutamatergic system in the mouse hippocampus: Implications for seizure susceptibility. Neuroscience, 2009, 161, 293-300.	2.3	78
133	Seizure Propensity and Brain Development: A Lesson from Animal Models. , 2009, , 77-104.		0
134	NPY gene transfer in the hippocampus attenuates synaptic plasticity and learning. Hippocampus, 2008, 18, 564-574.	1.9	55
135	Glia as a source of cytokines: Implications for neuronal excitability and survival. Epilepsia, 2008, 49, 24-32.	5.1	188
136	Inflammatory events in hippocampal slice cultures prime neuronal susceptibility to excitotoxic injury: a crucial role of P2X‹sub›7‹/sub› receptorâ€mediated ILâ€1Î² release. Journal of Neurochemistry, 2008, 106, 271-280.	3.9	78
137	Epileptogenic Role of Astrocyte Dysfunction. Epilepsy Currents, 2008, 8, 46-47.	0.8	6
138	Innate Immunity and Inflammation in Temporal Lobe Epilepsy: New Emphasis on the Role of Complement Activation. Epilepsy Currents, 2008, 8, 75-77.	0.8	25
139	VEGF as a Target for Neuroprotection. Epilepsy Currents, 2008, 8, 135-137.	0.8	14
140	Innate and adaptive immunity during epileptogenesis and spontaneous seizures: Evidence from experimental models and human temporal lobe epilepsy. Neurobiology of Disease, 2008, 29, 142-160.	4.4	618
141	Interleukin Converting Enzyme inhibition impairs kindling epileptogenesis in rats by blocking astrocytic IL-1Î² production. Neurobiology of Disease, 2008, 31, 327-333.	4.4	162
142	Acute induction of epileptiform discharges by pilocarpine in the in vitro isolated guinea-pig brain requires enhancement of bloodâ€“brain barrier permeability. Neuroscience, 2008, 151, 303-312.	2.3	74
143	The role of cytokines in the pathophysiology of epilepsy. Brain, Behavior, and Immunity, 2008, 22, 797-803.	4.1	474
144	Neuropeptide Y gene therapy decreases chronic spontaneous seizures in a rat model of temporal lobe epilepsy. Brain, 2008, 131, 1506-1515.	7.6	146

#	Article	IF	Citations
145	A novel non-transcriptional pathway mediates the proconvulsive effects of interleukin-1Â. Brain, 2008, 131, 3256-3265.	7.6	246
146	The promise of gene therapy for the treatment of epilepsy. Expert Review of Neurotherapeutics, 2007, 7, 1685-1692.	2.8	21
147	Gene therapy in epilepsy: The focus on NPY. Peptides, 2007, 28, 377-383.	2.4	62
148	New Roles for Interleukin-1 Beta in the Mechanisms of Epilepsy. Epilepsy Currents, 2007, 7, 45-50.	0.8	208
149	On Demand Up-regulation of Therapeutic Genes in the Brain: Fiction or Reality?. Epilepsy Currents, 2007, 7, 88-90.	0.8	0
150	Interleukinâ€1 System in CNS Stress. Annals of the New York Academy of Sciences, 2007, 1113, 173-177.	3.8	105
151	Status epilepticus induces time-dependent neuronal and astrocytic expression of interleukin-1 receptor type I in the rat limbic system. Neuroscience, 2006, 137, 301-308.	2.3	165
152	The Toll Receptor Family: From Microbial Recognition to Seizures. Epilepsy Currents, 2006, 6, 11-13.	0.8	3
153	Inhibition of the Multidrug Transporter P-Glycoprotein Improves Seizure Control in Phenytoin-treated Chronic Epileptic Rats. Epilepsia, 2006, 47, 672-680.	5.1	191
154	Inactivation of Caspase-1 in Rodent Brain: A Novel Anticonvulsive Strategy. Epilepsia, 2006, 47, 1160-1168.	5.1	159
155	In vitro responsiveness of human-drug-resistant tissue to antiepileptic drugs: Insights into the mechanisms of pharmacoresistance. Brain Research, 2006, 1086, 201-213.	2.2	20
156	Delayed administration of erythropoietin and its non-erythropoietic derivatives ameliorates chronic murine autoimmune encephalomyelitis. Journal of Neuroimmunology, 2006, 172, 27-37.	2.3	103
157	The IL-1Î² system in epilepsy-associated malformations of cortical development. Neurobiology of Disease, 2006, 24, 128-143.	4.4	249
158	Determinants of drug brain uptake in a rat model of seizure-associated malformations of cortical development. Neurobiology of Disease, 2006, 24, 429-442.	4.4	47
159	Gene Therapy for Epilepsy. , 2006, , 151-163.		1
160	Tissue Plasminogen Activator, Neuroserpin, and Seizures. Epilepsy Currents, 2005, 5, 130-132.	0.8	3
161	Inflammation and Epilepsy. Epilepsy Currents, 2005, 5, 1-6.	0.8	114
162	VEGF and Seizures: Cross-talk between Endothelial and Neuronal Environments. Epilepsy Currents, 2005, 5, 72-74.	0.8	10

#	Article	IF	Citations
163	A Pilot Study on Brain-to-Plasma Partition of 10,11-Dyhydro-10-hydroxy-5H-dibenzo(b,f)azepine-5-carboxamide and MDR1 Brain Expression in Epilepsy Patients Not Responding to Oxcarbazepine. Epilepsia, 2005, 46, 1613-1619.	5.1	86
164	Brain Inflammation in Epilepsy: Experimental and Clinical Evidence. Epilepsia, 2005, 46, 1724-1743.	5.1	921
165	Inflammatory Response and Glia Activation in Developing Rat Hippocampus after Status Epilepticus. Epilepsia, 2005, 46, 113-117.	5.1	149
166	Growth-associated Protein 43 Expression in Hippocampal Molecular Layer of Chronic Epileptic Rats Treated with Cycloheximide. Epilepsia, 2005, 46, 125-128.	5.1	53
167	The antiâ€epileptic actions of neuropeptide Y in the hippocampus are mediated by Y₂ and not Y₅ receptors. European Journal of Neuroscience, 2005, 22, 1417-1430.	2.6	114
168	Interleukin-1Î² contributes to the generation of experimental febrile seizures. Annals of Neurology, 2005, 57, 152-155.	5.3	379
169	Tumor necrosis factor-Î± inhibits seizures in mice via p75 receptors. Annals of Neurology, 2005, 57, 804-812.	5.3	182
170	Neuropeptide Y and Its Receptors in Kindling Epileptogenesis. , 2005, , 249-261.		0
171	Antiepileptic Effects of Botulinum Neurotoxin E. Journal of Neuroscience, 2005, 25, 1943-1951.	3.6	87
172	Altered expression of GABAa and GABAb receptor subunit mRNAs in the hippocampus after kindling and electrically induced status epilepticus. Neuroscience, 2005, 134, 691-704.	2.3	87
173	Neuropeptide Y Y5 receptors inhibit kindling acquisition in rats. Regulatory Peptides, 2005, 125, 79-83.	1.9	19
174	Modulator Effects of Interleukin-1Â and Tumor Necrosis Factor-Â on AMPA-Induced Excitotoxicity in Mouse Organotypic Hippocampal Slice Cultures. Journal of Neuroscience, 2005, 25, 6734-6744.	3.6	204
175	Anticonvulsant and Antiepileptogenic Effects Mediated by Adeno-Associated Virus Vector Neuropeptide Y Expression in the Rat Hippocampus. Journal of Neuroscience, 2004, 24, 3051-3059.	3.6	222
176	Functional Role of Proinflammatory and Anti-Inflammatory Cytokines in Seizures. Advances in Experimental Medicine and Biology, 2004, 548, 123-133.	1.6	43
177	Brain Inflammation and Seizures. Epilepsy Currents, 2004, 4, 73-75.	0.8	9
178	Gene Therapy in Epilepsy. Epilepsy Currents, 2004, 4, 87-90.	0.8	20
179	Neuropeptide Y and Y1 Receptors in Kindling Epileptogenesis. Epilepsy Currents, 2004, 4, 100-102.	0.8	0
180	Plasticity of somatostatin and somatostatin sst2A receptors in the rat dentate gyrus during kindling epileptogenesis. European Journal of Neuroscience, 2004, 19, 2531-2538.	2.6	24

#	Article	IF	Citations
181	Overexpression of NPY and Y2 receptors in epileptic brain tissue: an endogenous neuroprotective mechanism in temporal lobe epilepsy?. Neuropeptides, 2004, 38, 245-252.	2.2	150
182	Significance of MDR1 and multiple drug resistance in refractory human epileptic brain. BMC Medicine, 2004, 2, 37.	5.5	128
183	Selective and persistent upregulation of mdr1b mRNA and P-glycoprotein in the parahippocampal cortex of chronic epileptic rats. Epilepsy Research, 2004, 60, 203-213.	1.6	54
184	Sox2deficiency causes neurodegeneration and impaired neurogenesis in the adult mouse brain. Development (Cambridge), 2004, 131, 3805-3819.	2.5	587
185	Reduced anxiety and improved stress coping ability in mice lacking NPYâ€Y2 receptors. European Journal of Neuroscience, 2003, 18, 143-148.	2.6	173
186	Recombinant AAVâ€mediated expression of galanin in rat hippocampus suppresses seizure development. European Journal of Neuroscience, 2003, 18, 2087-2092.	2.6	109
187	Glia activation and cytokine increase in rat hippocampus by kainic acid-induced status epilepticus during postnatal development. Neurobiology of Disease, 2003, 14, 494-503.	4.4	214
188	Interleukin-1Î² Enhances NMDA Receptor-Mediated Intracellular Calcium Increase through Activation of the Src Family of Kinases. Journal of Neuroscience, 2003, 23, 8692-8700.	3.6	790
189	Seizure susceptibility and epileptogenesis are decreased in transgenic rats overexpressing neuropeptide Y. Neuroscience, 2002, 110, 237-243.	2.3	90
190	Limbic Seizures Induce P-Glycoprotein in Rodent Brain: Functional Implications for Pharmacoresistance. Journal of Neuroscience, 2002, 22, 5833-5839.	3.6	233
191	Expression of glutamate receptor subtypes in the spinal cord of control andmnd mice, a model of motor neuron disorder. Journal of Neuroscience Research, 2002, 70, 553-560.	2.9	25
192	Functional Role of Inflammatory Cytokines and Antiinflammatory Molecules in Seizures and Epileptogenesis. Epilepsia, 2002, 43, 30-35.	5.1	343
193	Somatostatin receptor subtypes 2 and 4 affect seizure susceptibility and hippocampal excitatory neurotransmission in mice. European Journal of Neuroscience, 2002, 16, 843-849.	2.6	77
194	Neuroprotective Effect of Somatostatin on Nonapoptotic NMDA-Induced Neuronal Death: Role of Cyclic GMP. Journal of Neurochemistry, 2002, 68, 319-327.	3.9	49
195	Dynamic induction of the long pentraxin PTX3 in the CNS after limbic seizures: evidence for a protective role in seizure-induced neurodegeneration. Neuroscience, 2001, 105, 43-53.	2.3	79
196	Autoradiographic Reevaluation of the Binding Properties of 125I-[Leu31,Pro34]Peptide YY and 125I-Peptide YY3-36 to Neuropeptide Y Receptor Subtypes in Rat Forebrain. Journal of Neurochemistry, 2001, 72, 1663-1670.	3.9	12
197	Inflammatory cytokines and related genes are induced in the rat hippocampus by limbic status epilepticus. European Journal of Neuroscience, 2000, 12, 2623-2633.	2.6	448
198	Modulatory Role of Neuropeptides in Seizures Induced in Rats by Stimulation of Glutamate Receptors. Journal of Nutrition, 2000, 130, 1046S-1048S.	2.9	34

#	Article	IF	Citations
199	Powerful anticonvulsant action of IL-1 receptor antagonist on intracerebral injection and astrocytic overexpression in mice. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 11534-11539.	7.1	424
200	Interleukin-1Î² Immunoreactivity and Microglia Are Enhanced in the Rat Hippocampus by Focal Kainate Application: Functional Evidence for Enhancement of Electrographic Seizures. Journal of Neuroscience, 1999, 19, 5054-5065.	3.6	536
201	Biochemical and pharmacological evidence of a functional role of AMPA receptors in motor neuron dysfunction inmndmice. European Journal of Neuroscience, 1999, 11, 1705-1710.	2.6	16
202	Brain somatostatin: a candidate inhibitory role in seizures and epileptogenesis. European Journal of Neuroscience, 1999, 11, 3767-3776.	2.6	129
203	Brain-derived neurotrophic factor immunoreactivity in the limbic system of rats after acute seizures and during spontaneous convulsions: temporal evolution of changes as compared to neuropeptide Y. Neuroscience, 1999, 90, 1445-1461.	2.3	99
204	Neuropeptide Y: emerging evidence for a functional role in seizure modulation. Trends in Neurosciences, 1999, 22, 25-30.	8.6	451
205	Anticonvulsant properties of BIBP3226, a nonâ€peptide selective antagonist at neuropeptide Y Y 1 receptors. European Journal of Neuroscience, 1998, 10, 757-759.	2.6	81
206	Timeâ€•and Regionâ€Specific Variations in Somatostatin Release Following Amygdala Kindling in the Rat. Journal of Neurochemistry, 1998, 70, 252-259.	3.9	7
207	Lasting Increase in Serotonin 5â€HT_{1A} but Not 5â€HT₄ Receptor Subtypes in the Kindled Rat Dentate Gyrus: Dissociation from Local Presynaptic Effects. Journal of Neurochemistry, 1998, 70, 850-857.	3.9	14
208	Distinct Changes in Peptide YY Binding to, and mRNA Levels of, Y1 and Y2 Receptors in the Rat Hippocampus Associated with Kindling Epileptogenesis. Journal of Neurochemistry, 1998, 70, 1615-1622.	3.9	70
209	Somatostatin-and Neuropeptide Y-Mediated Neurotransmission in Kindling Epileptogenesis. Advances in Behavioral Biology, 1998, , 313-325.	0.2	2
210	Agonists and Antagonists at Neuropeptide (i.e., Somatostatin and Neuropeptide Y) Receptors in the CNS [1,2]. Expert Opinion on Therapeutic Targets, 1997, 1, 101-103.	1.0	0
211	Autoradiographic analysis of neuropeptide Y receptor binding sites in the rat hippocampus after kainic acid-induced limbic seizures. Neuroscience, 1996, 70, 47-55.	2.3	70
212	Stimulation of 5â€HT_{1A} receptors in the dorsal hippocampus and inhibition of limbic seizures induced by kainic acid in rats. British Journal of Pharmacology, 1996, 119, 813-818.	5.4	48
213	Functional activation of somatostatin- and neuropeptide Y-containing neurons in the entorhinal cortex of chronically epileptic rats. Neuroscience, 1996, 75, 551-557.	2.3	19
214	Status of somatostatin receptor messenger RNAs and binding sites in rat brain during kindling epileptogenesis. Neuroscience, 1996, 75, 857-868.	2.3	18
215	Neuropeptides-immunoreactivity and their mRNA expression in kindling: functional implications for limbic epileptogenesis. Brain Research Reviews, 1996, 22, 27-50.	9.0	130
216	Cellular localization of neuropeptide-Y receptors in the rat hippocampus. NeuroReport, 1996, 7, 1475-1480.	1.2	18

#	Article	IF	Citations
217	Functional changes in somatostatin and neuropeptide Y containing neurons in the rat hippocampus in chronic models of limbic seizures. Epilepsy Research, 1996, 26, 267-279.	1.6	61
218	Regional Production of Nitric Oxide after a Peripheral or Central Low Dose of LPS in Mice. NeuroImmunoModulation, 1996, 3, 364-370.	1.8	6
219	Neuropeptides-immunoreactivity and their mRNA expression in kindling: functional implications for limbic epileptogenesis. Brain Research Reviews, 1996, 22, 27-50.	9.0	103
220	Functional activation of somatostatin and neuropeptide Y containing neurons in experimental models of limbic seizures. Epilepsy Research Supplement, 1996, 12, 187-95.	0.0	3
221	Alternative Splicing at the C-terminal but not at the N-terminal Domain of the NMDA Receptor NR1 is Altered in the Kindled Hippocampus. European Journal of Neuroscience, 1995, 7, 2513-2517.	2.6	31
222	Trans-synaptic Modulation of Striatal ACh ReleaseIn Vivoby the Parafascicular Thalamic Nucleus. European Journal of Neuroscience, 1995, 7, 1117-1120.	2.6	34
223	Extracellular glutamate levels in the hypothalamus and hippocampus of rats after acute or chronic oral intake of monosodium glutamate. Neuroscience Letters, 1995, 193, 45-48.	2.1	24
224	Electrical kindling is associated with a lasting increase in the extracellular levels of kynurenic acid in the rat hippocampus. Neuroscience Letters, 1995, 198, 91-94.	2.1	16
225	Functional effects of d-Phe-c[Cys-Tyr-d-Trp-Lys-Val-Cys]-Trp-NH2 and differential changes in somatostatin receptor messenger RNAs, binding sites and somatostatin release in kainic acid-treated rats. Neuroscience, 1995, 65, 1087-1097.	2.3	61
226	Somatostatin, neuropeptide Y, neurokinin B and cholecystokinin immunoreactivity in two chronic models of temporal lobe epilepsy. Neuroscience, 1995, 69, 831-845.	2.3	155
227	Enhanced neuropeptide Y release in the hippocampus is associated with chronic seizure susceptibility in kainic acid treated rats. Brain Research, 1994, 660, 138-143.	2.2	68
228	Adaptive changes in the NMDA receptor complex in rat hippocampus after chronic treatment with CGP 39551. European Journal of Pharmacology, 1994, 271, 93-101.	3.5	4
229	Impulse flow dependency of galanin release in vivo in the rat ventral hippocampus.. Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 8047-8051.	7.1	78
230	Changes in the ADP-ribosylation status of some hippocampal proteins are linked to kindling progression. NeuroReport, 1994, 5, 1217-1220.	1.2	7
231	Electrical Kindling of the Hippocampus is Associated with Functional Activation of Neuropeptide Y-containing Neurons. European Journal of Neuroscience, 1993, 5, 1534-1538.	2.6	67
232	Increased Expression of GAP-43, Somatostatin and Neuropeptide Y mRNA in the Hippocampus During Development of Hippocampal Kindling in Rats. European Journal of Neuroscience, 1993, 5, 1312-1320.	2.6	60
233	Extracellular Somatostatin Measured by Microdialysis in the Hippocampus of Freely Moving Rats: Evidence for Neuronal Release. Journal of Neurochemistry, 1993, 60, 671-677.	3.9	31
234	Anti-somatostatin antibody enhances the rate of hippocampal kindling in rats. Brain Research, 1993, 602, 148-152.	2.2	46

#	Article	IF	Citations
235	Somatostatin release is enhanced in the hippocampus of partially and fully kindled rats. Neuroscience, 1992, 51, 41-46.	2.3	44
236	Chronic infusion of quinolinic acid in rat striatum: effects on discrete neuronal populations. Journal of the Neurological Sciences, 1992, 108, 129-136.	0.6	21
237	Increased preproneuropeptide Y mRNA in the rat hippocampus during the development of hippocampal kindling: Comparison with the expression of preprosomatostatin mRNA. Neuroscience Letters, 1991, 132, 175-178.	2.1	36
238	Functional and histological consequences of quinolinic and kainic acid-induced seizures on hippocampal somatostatin neurons. Neuroscience, 1991, 41, 127-135.	2.3	39
239	Changes in pre- and postsynaptic components of noradrenergic transmission in hippocampal kindling in rats. Brain Research, 1991, 557, 210-216.	2.2	5
240	A peptidase-resistant cyclic octapeptide analogue of somatostatin (SMS 201â€“995) modulates seizures induced by quinolinic and kainic acids differently in the rat hippocampus. Neuropharmacology, 1991, 30, 345-352.	4.1	64
241	Epileptogenic Activity of Two Peptides Derived from Diazepam Binding Inhibitor After Intrahippocampal Injection in Rats. Epilepsia, 1991, 32, 597-603.	5.1	13
242	Neurodegenerative Effects Induced by Chronic Infusion of Quinolinic Acid in Rat Striatum and Hippocampus. European Journal of Neuroscience, 1991, 3, 40-46.	2.6	14
243	Kynurenic acid synthesis by human glioma. Journal of the Neurological Sciences, 1990, 99, 51-57.	0.6	14
244	Autoradiographical analysis of excitatory amino acid binding sites in rat hippocampus during the development of hippocampal kindling. Brain Research, 1990, 526, 113-121.	2.2	25
245	Effect of aspartame on seizures in various models of experimental epilepsy. Toxicology and Applied Pharmacology, 1988, 96, 485-493.	2.8	14
246	Quinolinic acid-induced seizures, but not nerve cell death, are associated with extracellular Ca2+ decrease assessed in the hippocampus by brain dialysis. Brain Research, 1988, 454, 289-297.	2.2	18
247	Effect of various calcium channel blockers on three different models of limbic seizures in rats. Neuropharmacology, 1988, 27, 451-458.	4.1	52
248	Role of the receptors in the development and maintenance of hippocampal kindling in rats. Neuroscience Letters, 1988, 87, 63-68.	2.1	191
249	Norepinephrine modulates seizures induced by quinolinic acid in rats: selective and distinct roles of Î±-adrenoceptor subtypes. European Journal of Pharmacology, 1987, 138, 309-318.	3.5	23
250	ATP as a marker of excitotoxin-induced nerve cell death in vivo. Journal of Neural Transmission, 1987, 70, 349-356.	2.8	6
251	[3H]Norepinephrine Release from Hippocampal Slices Is an In Vitro Biochemical Tool for Investigating the Pharmacological Properties of Excitatory Amino Acid Receptors. Journal of Neurochemistry, 1987, 49, 1438-1442.	3.9	69
252	Determination of Endogenous Acetylcholine Release in Freely Moving Rats by Transstriatal Dialysis Coupled to a Radioenzymatic Assay: Effect of Drugs. Journal of Neurochemistry, 1987, 48, 1459-1465.	3.9	107

#	Article	IF	Citations
253	In vivo and in vitro studies on the regulation of cholinergic neurotransmission in striatum, hippocampus and cortex of aged rats. Brain Research, 1986, 374, 212-218.	2.2	58
254	Anticonvulsant drugs effective against human temporal lobe epilepsy prevent seizures but not neurotoxicity induced in rats by quinolinic acid: electroencephalographic, behavioral and histological assessments. Journal of Pharmacology and Experimental Therapeutics, 1986, 239, 256-63.	2.5	30
255	In Vivo Brain Dialysis of Amino Acids and Simultaneous EEG Measurements Following Intrahippocampal Quinolinic Acid Injection: Evidence for a Dissociation Between Neurochemical Changes and Seizures. Journal of Neurochemistry, 1985, 45, 335-344.	3.9	102
256	A noradrenergic component of quinolinic acid-induced seizures. Experimental Neurology, 1985, 90, 254-258.	4.1	14
257	Kynurenic acid blocks neurotoxicity and seizures induced in rats by the related brain metabolite quinolinic acid. Neuroscience Letters, 1984, 48, 273-278.	2.1	387
258	Mode of action of gamma-butyrolactone on the central cholinergic system. Naunyn-Schmiedeberg's Archives of Pharmacology, 1983, 322, 42-48.	3.0	28